Assessment of Public Opinion on Transparency at the US Food and Drug Administration

Azad, Tej D.; Plott, Caroline F.; Gielen, Andrea; Sharfstein, Joshua M.

doi:10.1001/jamanetworkopen.2022.0026

Cited by 1 publication

(1 citation statement)

References 5 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…82 The Agency would, therefore, surely face funding pressures from politicians and special interests (in line with Baker‘s warnings 1 ), even if the pharmaceutical companies, with lower profits at stake, would have less reason to lobby Congress. These pressures can be resisted, to a large degree, by insisting on transparency (as the public also wants 83 ) and by relying at all stages on the advice and judgments of independent experts.…”

Section: Responses To Likely Objectionsmentioning

confidence: 99%

A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals

et al. 2022

View full text Add to dashboard Cite

The process of developing and marketing new pharmaceuticals in the United States is driven by a need to maximize returns to shareholders. This results all too often in the production of new medications that are expensive and of marginal value to patients and society. In line with our heightened awareness of the importance of social justice and public health—and in light of our government‘s alliance with private companies in bringing us COVID-19 vaccines—we need to reconsider how new pharmaceuticals are developed and distributed. Accordingly, we propose the creation of a new agency of the Food and Drug Administration (FDA) that would direct the whole process. This agency would fund the research and development of high-value medications, closely monitor the clinical studies of these new drugs, and manage their distribution at prices that are value-based, fair, and equitable.

show abstract

Section: Responses To Likely Objectionsmentioning

confidence: 99%

A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals

et al. 2022

View full text Add to dashboard Cite

show abstract

Assessment of Public Opinion on Transparency at the US Food and Drug Administration

Abstract: Author Contributions: Drs Azad and Sharfstein had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Cited by 1 publication

References 5 publications

A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals

A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals

Contact Info

Product

Resources

About